Skip to content
10-Q

Quarterly Report

CYCLERION THERAPEUTICS, INC. CYCN

0000950170-24-092257

← back to feed
Filed
Aug 7, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 5, 2024 2.71M sh
Cash And Equivalents Q2 2024 · Jun 30, 2024 $4.59M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $7.57M
Stockholders Equity Q2 2024 · Jun 30, 2024 $8.78M
Stockholders Equity Q2 2024 · Mar 31, 2024 $9.92M
Stockholders Equity Q2 2024 · Dec 31, 2023 $11.29M
Stockholders Equity Q2 2024 · Jun 30, 2023 $5.15M
Stockholders Equity Q2 2024 · Mar 31, 2023 $3.93M
Stockholders Equity Q2 2024 · Dec 31, 2022 $10.45M
Current Liabilities Q2 2024 · Jun 30, 2024 $1.28M
Current Liabilities Q2 2024 · Dec 31, 2023 $2.09M
Current Assets Q2 2024 · Jun 30, 2024 $4.72M
Current Assets Q2 2024 · Dec 31, 2023 $8.02M
Total Assets Q2 2024 · Jun 30, 2024 $10.07M
Total Assets Q2 2024 · Dec 31, 2023 $13.37M
Shares Diluted Q2 2024 · Jun 30, 2023 2.28M sh
Shares Diluted Q2 2024 · Jun 30, 2023 2.23M sh
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$12.77M
Eps Diluted Q2 2024 · Jun 30, 2023 −$1.83
Eps Diluted Q2 2024 · Jun 30, 2023 −$5.00
Eps Basic Q2 2024 · Jun 30, 2023 −$1.83
Eps Basic Q2 2024 · Jun 30, 2023 −$5.00
Sga Expense restated Q2 2024 · Jun 30, 2023 $1.53M
Sga Expense restated Q2 2024 · Jun 30, 2023 $4.23M
Rd Expense restated Q2 2024 · Jun 30, 2023 $339K
Rd Expense restated Q2 2024 · Jun 30, 2023 $911K
Net Income Q2 2024 · Jun 30, 2023 −$4.18M
Net Income Q2 2024 · Jun 30, 2023 −$11.14M
Net Income Q2 2024 · Mar 31, 2023 −$6.95M
Operating Income restated Q2 2024 · Jun 30, 2023 −$1.87M
Operating Income restated Q2 2024 · Jun 30, 2023 −$5.14M